Fibromyalgia syndrome (FM) is a chronic widespread pain syndrome characterised by
fatigue, sleep disturbances and many idiopathic pain symptoms. The aim of this review is to …

This paper is the forty-fifth consecutive installment of the annual anthological review of
research concerning the endogenous opioid system, summarizing articles published during …

Fibromyalgia (FM) is a chronic pain sensitivity syndrome characterized by diffuse
musculoskeletal pain and many other systemic manifestations. Low-dose naltrexone (LDN) …

Opioid-induced hyperalgesia (OIH) is a paradoxical effect of opioids that is not consensually
recognized in clinical settings. We conducted a revision of clinical and preclinical studies …

Objectives: First, to examine if LDN is associated with analgesic efficacy compared with
control in the treatment of patients with FM. Second, to ascertain the analgesic efficacy of …

Background: Dysfunction at the ocular system via nociceptive or neuropathic mechanisms
can lead to chronic ocular pain. While many studies have reported on responses to …

Chronic pain is highly prevalent in patients with cirrhosis and is associated with poor health‐
related quality of life and poor functional status. However, there is limited guidance on …

Introduction There is evidence that low-dose naltrexone (LDN;< 5.0 mg/day) reduces pain
and improves the quality of life of people with fibromyalgia syndrome (FMS). However, no …

Chronic pain conditions create major financial and emotional burdens that can be
devastating for individuals and society. One primary source of pain is arthritis, a common …

Background At low doses, naltrexone (LDN) has been shown to modulate inflammation
through the interruption of microglial cell activation within the central nervous system. One of …